A detailed history of Los Angeles Capital Management LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 123,401 shares of TGTX stock, worth $3.86 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
123,401
Previous 92,277 33.73%
Holding current value
$3.86 Million
Previous $1.64 Million 75.87%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$17.21 - $25.28 $535,644 - $786,814
31,124 Added 33.73%
123,401 $2.89 Million
Q2 2024

Aug 05, 2024

BUY
$13.32 - $19.19 $208,604 - $300,534
15,661 Added 20.44%
92,277 $1.64 Million
Q1 2024

Apr 05, 2024

BUY
$13.02 - $21.3 $357,229 - $584,408
27,437 Added 55.79%
76,616 $1.17 Million
Q3 2023

Nov 06, 2023

SELL
$8.36 - $26.5 $16,987 - $53,848
-2,032 Reduced 3.97%
49,179 $411,000
Q2 2023

Aug 03, 2023

SELL
$15.48 - $35.0 $155,512 - $351,610
-10,046 Reduced 16.4%
51,211 $1.27 Million
Q1 2023

May 04, 2023

SELL
$10.23 - $19.34 $1 Million - $1.9 Million
-98,053 Reduced 61.55%
61,257 $921,000
Q4 2022

Feb 06, 2023

SELL
$5.01 - $11.83 $19,564 - $46,196
-3,905 Reduced 2.39%
159,310 $1.88 Million
Q3 2022

Nov 02, 2022

BUY
$4.57 - $8.4 $166,846 - $306,675
36,509 Added 28.81%
163,215 $966,000
Q2 2022

Aug 05, 2022

BUY
$3.74 - $10.66 $435,508 - $1.24 Million
116,446 Added 1134.95%
126,706 $539,000
Q1 2022

May 06, 2022

BUY
$7.81 - $20.45 $21,516 - $56,339
2,755 Added 36.71%
10,260 $98,000
Q2 2021

Aug 05, 2021

SELL
$32.5 - $48.96 $147,712 - $222,523
-4,545 Reduced 37.72%
7,505 $291,000
Q1 2021

May 05, 2021

BUY
$41.61 - $54.3 $501,400 - $654,315
12,050 New
12,050 $580,000
Q3 2020

Nov 02, 2020

SELL
$18.49 - $27.24 $214,447 - $315,929
-11,598 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$8.9 - $21.84 $103,222 - $253,300
11,598 New
11,598 $225,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.54B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.